Related Experiment Video
Updated: May 16, 2026
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers
Aida Attar1, Cristian Ripoli, Elisa Riccardi
1Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Neuroscience Research Building 1, Room 451, 635 Charles E. Young Drive South, Los Angeles, CA 90095-7334, USA. gbitan@mednet.ucla.edu
Abstract:
Alzheimer's disease is a devastating cureless neurodegenerative disorder affecting >35 million people worldwide. The disease is caused by toxic oligomers and aggregates of amyloid β protein and the microtubule-associated protein tau. Recently, the Lys-specific molecular tweezer CLR01 has been shown to inhibit aggregation and toxicity of multiple amyloidogenic proteins, including amyloid β protein and tau, by disrupting key interactions involved in the assembly process. Following up on these encouraging findings, here, we asked whether CLR01 could protect primary neurons from Alzheimer's disease-associated synaptotoxicity and reduce Alzheimer's disease-like pathology in vivo. Using cell culture and brain slices, we found that CLR01 effectively inhibited synaptotoxicity induced by the 42-residue isoform of amyloid β protein, including ∼80% inhibition of changes in dendritic spines density and long-term potentiation and complete inhibition of changes in basal synaptic activity. Using a radiolabelled version of the compound, we found that CLR01 crossed the mouse blood-brain barrier at ∼2% of blood levels. Treatment of 15-month-old triple-transgenic mice for 1 month with CLR01 resulted in a decrease in brain amyloid β protein aggregates, hyperphosphorylated tau and microglia load as observed by immunohistochemistry. Importantly, no signs of toxicity were observed in the treated mice, and CLR01 treatment did not affect the amyloidogenic processing of amyloid β protein precursor. Examining induction or inhibition of the cytochrome P450 metabolism system by CLR01 revealed minimal interaction. Together, these data suggest that CLR01 is safe for use at concentrations well above those showing efficacy in mice. The efficacy and toxicity results support a process-specific mechanism of action of molecular tweezers and suggest that these are promising compounds for developing disease-modifying therapy for Alzheimer's disease and related disorders.
Insights
The molecular tweezer CLR01 effectively protected neurons from Alzheimer's disease-related damage and reduced key disease pathologies in mice. This compound shows promise as a safe, disease-modifying therapy for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease is a neurodegenerative disorder linked to amyloid-beta and tau protein aggregation.
- Current treatments are limited, necessitating novel therapeutic strategies.
- Molecular tweezers, like CLR01, show potential in disrupting protein aggregation.
Purpose of the Study:
- To evaluate CLR01's efficacy in protecting neurons from Alzheimer's disease-associated synaptotoxicity.
- To assess CLR01's ability to reduce Alzheimer's disease-like pathology in vivo.
- To determine the safety and blood-brain barrier penetration of CLR01.
Main Methods:
- In vitro studies using primary neurons and brain slices to assess synaptotoxicity.
- In vivo studies using a triple-transgenic mouse model of Alzheimer's disease.
- Immunohistochemistry to evaluate amyloid-beta aggregates, hyperphosphorylated tau, and microglia.
- Pharmacokinetic studies to determine blood-brain barrier penetration and toxicity assessments.
Main Results:
- CLR01 significantly inhibited amyloid-beta-induced synaptotoxicity, including dendritic spine density and long-term potentiation.
- The compound effectively reduced amyloid-beta aggregates, hyperphosphorylated tau, and microglia load in the brains of treated mice.
- CLR01 demonstrated good blood-brain barrier penetration and was well-tolerated, with no observed toxicity or impact on amyloid precursor processing.
Conclusions:
- CLR01 is a promising therapeutic candidate for Alzheimer's disease, demonstrating both efficacy and safety.
- Molecular tweezers offer a novel, process-specific mechanism for developing disease-modifying therapies.
- Further research into CLR01 and similar compounds could lead to effective treatments for Alzheimer's and related neurodegenerative disorders.
